TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18694831

Group type: EXPERIMENTAL
Intervention: CYP2C9*3 allele
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CYP2C8*3 allele
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CYP2C8*3
Number of subjects: 69

Group type: COMPARATOR
Intervention: CYP2C8*1
Number of subjects: 69
Study: 16880097

Group type: EXPERIMENTAL
Intervention: Plasma NT‐proBNP levels in patients with LV systolic dysfunction (LVEF < 55%)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Plasma NT‐proBNP levels in patients with normal LV systolic function (LVEF >= 55%)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Healthy control subjects (n = 43)
Number of subjects: 191
Study: 14600932

Group type: EXPERIMENTAL
Intervention: Physical stress during myocardial perfusion SPECT study
Number of subjects: 46
Study: 10831560

Group type: EXPERIMENTAL
Intervention: 250 microg recombinant human chorionic gonadotrophin (rHCG; Ovidrel)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 5000 IU urinary HCG (uHCG; Profasi)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: rHCG
Number of subjects: 84

Group type: COMPARATOR
Intervention: uHCG
Number of subjects: 84
Study: 8669268

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg a day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg a day (combined with Cetirizine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Budesonide (Rhinocort Aqua)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Azelastine (Allergodil nasal spray)
Number of subjects: 30
Study: 1611372

Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for acute cough
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for acute vomiting
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for itchy rash
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for recurrent wheezy chest
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for bedwetting
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 3500
Study: 6395279

Group type: EXPERIMENTAL
Intervention: Multiple-dose cefoxitin
Number of subjects: 301

Group type: COMPARATOR
Intervention: Single-dose cefonicid
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 301
Study: 30992306

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone and Naltrexone (combined)
Number of subjects: 0
Study: 29577681

Group type: EXPERIMENTAL
Intervention: Radotinib (400 mg once daily)
Number of subjects: 0
Study: 27013382

Group type: EXPERIMENTAL
Intervention: Zenpep (25,000 lipase units)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Kreon (25,000 lipase units)
Number of subjects: 96
Study: 24475284

Group type: EXPERIMENTAL
Intervention: E. coli endotoxin (lipopolysaccharide, LPS) 0.3 ng/kg at 12 noon
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: E. coli endotoxin (lipopolysaccharide, LPS) 0.3 ng/kg at 12 midnight
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no endotoxin administration)
Number of subjects: 12
Study: 22776778

Group type: EXPERIMENTAL
Intervention: 5 mg saxagliptin QD + COC QD for 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: COC (Ortho-Cyclen) once daily for 21 days
Number of subjects: 20
Study: 21135325

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Maintenance antidepressant medication
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 17486631

Group type: EXPERIMENTAL
Intervention: Defendants with mental retardation (MR) and mentally typical defendants (non-MR) instructed to fake performance on the test.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard conditions for MR and non-MR defendants taking the test.
Number of subjects: 0
Study: 16023249

Group type: EXPERIMENTAL
Intervention: Fractionated plasma separation (FPS, Prometheus)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Albumin dialysis (AD, MARS)
Number of subjects: 8
Study: 12613056

Group type: EXPERIMENTAL
Intervention: Multiple educational interventions including two-way communications, printed and graphic materials, and locally respected health personnel as educators.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cost-effective educational methods that can be generalized to other physician groups.
Number of subjects: 20
Study: 9861123

Group type: EXPERIMENTAL
Intervention: Morphine 0.3 mg kg-1 at induction of anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (morphine given 30 min later at skin incision)
Number of subjects: 0
Study: 9243217

Group type: EXPERIMENTAL
Intervention: Fluorometholone-Gentamicin eye drops
Number of subjects: 112

Group type: COMPARATOR
Intervention: Maxitrol (dexamethasone, neomycin, polymyxin B) eye drops
Number of subjects: 112
Study: 2664670

Group type: EXPERIMENTAL
Intervention: Intraoperative and postoperative cefuroxime (1500 mg and 750 mg intravenously, followed by 750 mg every eight hours for 24 hours postoperatively)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Intraoperative cefuroxime (1500 mg and 750 mg intravenously)
Number of subjects: 196
Study: 1276626

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy followed by chemotherapy
Number of subjects: 373

Group type: COMPARATOR
Intervention: Radiotherapy restricted to the pelvic area
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Whole-abdomen irradiation
Number of subjects: 373
Study: 31883418

Group type: EXPERIMENTAL
Intervention: Avelumab + axitinib
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 67
Study: 31170077

Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA, 20 min, anodal electrode on M1 area of affected hemisphere)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS (5 s) during wrist robotic rehabilitation training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Real tDCS and Sham tDCS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of wrist robot-assisted training and tDCS
Number of subjects: 40
Study: 28500815

Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline plus pentavalent antimony (Sbv)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo plus pentavalent antimony (Sbv)
Number of subjects: 164
Study: 26307212

Group type: EXPERIMENTAL
Intervention: Personalized interactive mobile health intervention (iSTEP)
Number of subjects: 21
Study: 24064689

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) 50 mg weekly
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 21261667

Group type: EXPERIMENTAL
Intervention: Exercise group (specific exercises aimed at strengthening or stretching the shoulder girdle, completed 3 days per week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (standard instructions)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 19166975

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16940979

Group type: EXPERIMENTAL
Intervention: Systematic lymphadenectomy (SL)
Number of subjects: 268
Study: 15116984

Group type: EXPERIMENTAL
Intervention: Spatial mapping analogous to symbolic mapping (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mappings conducive to simple transformational rules (Experiments 2 and 3)
Number of subjects: 0
Study: 11277687

Group type: EXPERIMENTAL
Intervention: Sedentary individuals
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Less education
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Nonmarried status
Number of subjects: 1322
Study: 9237594

Group type: EXPERIMENTAL
Intervention: IABP 1 day prior to surgery
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IABP 1-2 h prior to CPB
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no preoperative IABP)
Number of subjects: 52
Study: 8513189

Group type: EXPERIMENTAL
Intervention: Fulguration under EMLA anaesthesia
Number of subjects: 22

Group type: COMPARATOR
Intervention: Topical tretinoin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Light electrocautery using EMLA anaesthetic
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fulguration without anaesthesia
Number of subjects: 22
Study: 2446060

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg) + Hydrochlorothiazide (25 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg) + Hydrochlorothiazide (12.5 mg)
Number of subjects: 35
Study: 29724188

Group type: EXPERIMENTAL
Intervention: Spironolactone 25-50 mg/day
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 27110370

Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg, once daily)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Voglibose (0.6 mg, thrice daily)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 260
Study: 25181763

Group type: EXPERIMENTAL
Intervention: Social Cognitive Theory‐based Internet intervention
Number of subjects: 220
Study: 22430690

Group type: EXPERIMENTAL
Intervention: Lateral condensation technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thermafil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-step technique
Number of subjects: 0
Study: 20633748

Group type: EXPERIMENTAL
Intervention: Pegylated interferon treatment (IFA) for 24 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 30
Study: 18691996

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Pravastatin 20 mg
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Rosuvastatin vs Pravastatin 20 mg
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Rosuvastatin vs Simvastatin
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Rosuvastatin vs Pravastatin
Number of subjects: 2268
Study: 15777327

Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene membrane only (Group 1, n=12)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Resorbable polylactide/polyglycolide copolymer membrane only (Group 2, n=11)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Resorbable membrane and autogenous bone graft (Group 3, n=13)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Autogenous bone graft only (Group 4, n=14)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No membrane and no bone graft (Group 5, n=12)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Membrane use (Groups 1, 2, and 3)
Number of subjects: 62
Study: 12464950

Group type: EXPERIMENTAL
Intervention: Budesonide 0.8 mg/daily for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide 0.8 mg/daily for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide 0.8 mg/daily
Number of subjects: 0
Study: 10028208

Group type: EXPERIMENTAL
Intervention: Community-based advocacy intervention
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 278
Study: 7573091

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 40 mg methylprednisolone acetate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 40 mg methylprednisolone acetate
Number of subjects: 21
Study: 2207001

Group type: EXPERIMENTAL
Intervention: Testicular irradiation
Number of subjects: 246

Group type: COMPARATOR
Intervention: No testicular irradiation (Control)
Number of subjects: 246
Study: 347989

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30160577

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28369340

Group type: EXPERIMENTAL
Intervention: Vericiguat (10 mg)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Vericiguat (pooled three highest dose arms)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 25648342

Group type: EXPERIMENTAL
Intervention: Combination treatment with injectable testosterone undecanoate (1,000 mg on day 1, additional injections at weeks 6 and 18) and daily tadalafil (5 mg) for 30 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination treatment with injectable testosterone undecanoate (1,000 mg on day 1, additional injections at weeks 6 and 18) and on-demand tadalafil (10-20 mg) for 30 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group receiving the same testosterone treatment but with on-demand tadalafil (10-20 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group II (daily tadalafil 5 mg)
Number of subjects: 60
Study: 22882805

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 269
Study: 21198671

Group type: EXPERIMENTAL
Intervention: Live attenuated vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated vaccines with oil-in-water emulsion adjuvants (e.g., MF59)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adjuvanted inactivated vaccines
Number of subjects: 0
Study: 18945572

Group type: EXPERIMENTAL
Intervention: Interactive multimedia CD-ROM
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard written information
Number of subjects: 101
Study: 16513877

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 61
Study: 12937039

Group type: EXPERIMENTAL
Intervention: Urine polymerase chain reaction (PCR)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Urine culture
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Serum CMV IgM antibodies
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Full clinical evaluation
Number of subjects: 2000
Study: 11106042

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (50 mg/kg)
Number of subjects: 167
Study: 9345158

Group type: EXPERIMENTAL
Intervention: Mandibular lingual arch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 8243687

Group type: EXPERIMENTAL
Intervention: T enanthate + depot‐MPA
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 19‐nortestosterone ester + depot‐MPA
Number of subjects: 96

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 19‐nortestosterone group
Number of subjects: 96
Study: 3545882

Group type: EXPERIMENTAL
Intervention: Biostim 2 mg/day
Number of subjects: 198

Group type: COMPARATOR
Intervention: Biostim 8 mg/day
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 31503274

Group type: EXPERIMENTAL
Intervention: Methotrexate (25mg weekly)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (3g daily)
Number of subjects: 216
Study: 29710284

Group type: EXPERIMENTAL
Intervention: ACS guidelines score of 5 to 6 (n=91; 9%)
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: ACS guidelines score of 6 to 8 (n=162; 16%)
Number of subjects: 992

Group type: COMPARATOR
Intervention: ACS guidelines score of 0 to 1 (n=262; 26%)
Number of subjects: 992

Group type: COMPARATOR
Intervention: ACS guidelines score of 0 to 2 (n=187; 91%)
Number of subjects: 992
Study: 28053650

Group type: EXPERIMENTAL
Intervention: Local Difference Pattern (LDP) and combined classifier
Number of subjects: 0
Study: 24383914

Group type: EXPERIMENTAL
Intervention: Vi vaccine (Typherix(®))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ty21a vaccine (Vivotif(®))
Number of subjects: 50
Study: 22517480

Group type: EXPERIMENTAL
Intervention: Patients informed of monitoring (10 patients)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Patients uninformed of monitoring (11 patients)
Number of subjects: 21
Study: 20143119

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 44
Study: 16638070

Group type: EXPERIMENTAL
Intervention: Applied criteria for detecting individuals at risk of psychosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15849398

Group type: EXPERIMENTAL
Intervention: Antibiotics (group A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: No antibiotics (group B)
Number of subjects: 87
Study: 11296170

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) with two cycles of two‐min ischemia followed by 3‐min reperfusion before cross‐clamping
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no ischemic preconditioning)
Number of subjects: 40
Study: 9257789

Group type: EXPERIMENTAL
Intervention: 200 microg of budesonide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 800 microg of budesonide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D5159 (8 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8421248

Group type: EXPERIMENTAL
Intervention: Caffeine 1.5 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine 3.0 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (0.0 mg/kg caffeine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Introverts
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Extraverts
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 24
Study: 3555276

Group type: EXPERIMENTAL
Intervention: 75 mg of diclofenac
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study: 31327292

Group type: EXPERIMENTAL
Intervention: Twice weekly group-exercises and physical activity counselling
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 80
Study: 30483937

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (ten sessions with three types of wavelengths)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (untreated side of the scars)
Number of subjects: 17
Study: 29421002

Group type: EXPERIMENTAL
Intervention: Edoxaban-based strategy (60 mg or 30 mg once daily) plus P2Y12 antagonist (clopidogrel, 75 mg once daily) for 12 months
Number of subjects: 1500

Group type: COMPARATOR
Intervention: VKA-based strategy (VKA plus P2Y12 antagonist and acetylsalicylic acid 100 mg once daily) for 30 days to 12 months
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Edoxaban-based strategy
Number of subjects: 1500

Group type: COMPARATOR
Intervention: VKA-based strategy
Number of subjects: 1500
Study: 27480131

Group type: EXPERIMENTAL
Intervention: CPP‐1X 750 mg and sulindac 150 mg
Number of subjects: 138

Group type: COMPARATOR
Intervention: CPP‐1X placebo and sulindac 150 mg
Number of subjects: 138

Group type: COMPARATOR
Intervention: CPP‐1X 750 mg and sulindac placebo
Number of subjects: 138
Study: 24793258

Group type: EXPERIMENTAL
Intervention: Sun-related behaviour (suntan, sunbathing, sunburn, sunscreen use, sunbed use)
Number of subjects: 2173

Group type: EXPERIMENTAL
Intervention: Skin cancer awareness
Number of subjects: 2173

Group type: EXPERIMENTAL
Intervention: Tanning attitudes
Number of subjects: 2173

Group type: EXPERIMENTAL
Intervention: Gender differences in sun-related behaviours
Number of subjects: 2173
Study: 21935581

Group type: EXPERIMENTAL
Intervention: Left atrial epicardial cryoablation and LAA closure (ABL group, n=30)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Mitral valve surgery alone (control group, n=35)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Left atrial epicardial cryoablation and LAA closure (ABL group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Mitral valve surgery alone (control group)
Number of subjects: 65
Study: 20620634

Group type: EXPERIMENTAL
Intervention: Symptom criteria alone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Symptom criteria plus nasal endoscopy
Number of subjects: 202
Study: 18418791

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 182

Group type: COMPARATOR
Intervention: Equal contact control
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 182
Study: 17198904

Group type: EXPERIMENTAL
Intervention: C12 Peptide (3.8 g daily for 4 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12603176

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg twice daily for 5.5 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg once daily for 6 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg twice daily and Simvastatin 40 mg once daily
Number of subjects: 9
Study: 10649881

Group type: EXPERIMENTAL
Intervention: Counter-rotational powered toothbrush
Number of subjects: 2966

Group type: COMPARATOR
Intervention: Manual methods
Number of subjects: 2966
Study: 9096658

Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) >4,000 mg/m2
Number of subjects: 604

Group type: COMPARATOR
Intervention: None (AGDS cohort)
Number of subjects: 604
Study: 8117631

Group type: EXPERIMENTAL
Intervention: SPGBlidocaine
Number of subjects: 16

Group type: COMPARATOR
Intervention: SPGBsaline
Number of subjects: 16
Study: 3516764

Group type: EXPERIMENTAL
Intervention: Fructose-enriched meals
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sucrose-enriched meals
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bread-enriched meals
Number of subjects: 7
Study: 29185087

Group type: EXPERIMENTAL
Intervention: Assistive devices for daily life activities
Number of subjects: 39

Group type: COMPARATOR
Intervention: Guideline leaflet with information on joint protection and disease features
Number of subjects: 39